Allergy Therapeutics (AGY) - Total Assets
Based on the latest financial reports, Allergy Therapeutics (AGY) holds total assets worth GBX67.54 Million GBX (≈ $8.22K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AGY cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Allergy Therapeutics - Total Assets Trend (2002–2025)
This chart illustrates how Allergy Therapeutics's total assets have evolved over time, based on quarterly financial data. See AGY net asset value for net asset value and shareholders' equity analysis.
Allergy Therapeutics - Asset Composition Analysis
Current Asset Composition (June 2025)
Allergy Therapeutics's total assets of GBX67.54 Million consist of 51.3% current assets and 48.7% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 18.9% |
| Accounts Receivable | GBX7.97 Million | 11.8% |
| Inventory | GBX13.91 Million | 20.6% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX931.00K | 1.4% |
| Goodwill | GBX3.33 Million | 4.9% |
Asset Composition Trend (2002–2025)
This chart illustrates how Allergy Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AGY market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Allergy Therapeutics's current assets represent 51.3% of total assets in 2025, an increase from 37.0% in 2002.
- Cash Position: Cash and equivalents constituted 18.9% of total assets in 2025, up from 0.6% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 49.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 20.6% of total assets.
Allergy Therapeutics Competitors by Total Assets
Key competitors of Allergy Therapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Alkermes plc
F:8AK
|
Germany | €4.26 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
|
China | CN¥6.49 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
Allergy Therapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.28 | 1.63 | 3.03 |
| Quick Ratio | 0.76 | 1.01 | 2.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX7.49 Million | GBX12.94 Million | GBX36.94 Million |
Allergy Therapeutics - Advanced Valuation Insights
This section examines the relationship between Allergy Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.15 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | GBX67.54 Million |
| Market Capitalization | $3.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Allergy Therapeutics's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Allergy Therapeutics's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Allergy Therapeutics (2002–2025)
The table below shows the annual total assets of Allergy Therapeutics from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | GBX67.54 Million ≈ $8.22K |
+4.19% |
| 2024-06-30 | GBX64.83 Million ≈ $7.89K |
-2.91% |
| 2023-06-30 | GBX66.77 Million ≈ $8.12K |
-8.47% |
| 2022-06-30 | GBX72.95 Million ≈ $8.88K |
-17.19% |
| 2021-06-30 | GBX88.09 Million ≈ $10.72K |
+2.16% |
| 2020-06-30 | GBX86.22 Million ≈ $10.49K |
+25.88% |
| 2019-06-30 | GBX68.50 Million ≈ $8.33K |
+34.27% |
| 2018-06-30 | GBX51.02 Million ≈ $6.21K |
-10.78% |
| 2017-06-30 | GBX57.18 Million ≈ $6.96K |
+0.89% |
| 2016-06-30 | GBX56.68 Million ≈ $6.90K |
+11.80% |
| 2015-06-30 | GBX50.70 Million ≈ $6.17K |
+78.53% |
| 2014-06-30 | GBX28.40 Million ≈ $3.46K |
-1.95% |
| 2013-06-30 | GBX28.96 Million ≈ $3.52K |
+4.36% |
| 2012-06-30 | GBX27.75 Million ≈ $3.38K |
-9.36% |
| 2011-06-30 | GBX30.62 Million ≈ $3.73K |
+5.17% |
| 2010-06-30 | GBX29.11 Million ≈ $3.54K |
+31.88% |
| 2009-06-30 | GBX22.08 Million ≈ $2.69K |
-4.77% |
| 2008-06-30 | GBX23.18 Million ≈ $2.82K |
-3.38% |
| 2007-06-30 | GBX23.99 Million ≈ $2.92K |
-36.66% |
| 2006-06-30 | GBX37.88 Million ≈ $4.61K |
+42.09% |
| 2005-06-30 | GBX26.66 Million ≈ $3.24K |
+137.32% |
| 2004-06-30 | GBX11.23 Million ≈ $1.37K |
+0.76% |
| 2003-06-30 | GBX11.15 Million ≈ $1.36K |
+15.22% |
| 2002-06-30 | GBX9.68 Million ≈ $1.18K |
-- |
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more